Your browser does not support JavaScript!

Fabricants distributeurs d'instruments de mesure

389 entreprises et organismes intervenants dans le domaine 'Instruments de mesure', classés par activité.

Rejoignez la communauté
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Il y a 4 jours

EuroBiotech Report—UCB inks $2.5B deal; Oxford spinout; Bayer, Merck and Gilead

Il y a 5 jours
In this week's EuroBiotech Report, UCB inks $2.5 billion Ra takeout, MiroBio raises £27 million and Bayer forms Riken drug discovery pact. ...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de Labiotech.eu
Il y a 6 jours

UK Company and Merck Team Up to Develop Vaccines Based on the Microbiome

Il y a 1 semaine
Merck will pay the microbiome company 4D Pharma up to €316.5M to develop vaccines based on delivering live bacteria to the gut. The partners will develop vaccines against three undisclosed conditions....
www.labiotech.eu
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Il y a 2 semaines

ESMO: AbbVie's PARP inhibitor veliparib finally gets a win, but can it compete?

Il y a 2 semaines
BARCELONA—Quietly, and without the fanfare of gene and cell therapies, PARP inhibitors from the likes of AstraZeneca, Merck and GlaxoSmithKline/Tesaro have been racking up big trial wins in breast and...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Il y a 3 semaines

Black Diamond grabs trio of new R&D execs as it barrels toward the clinic

Il y a 3 semaines
After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up its research work....
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Il y a 3 semaines

Merck's Ebola vaccine tees up FDA date, aiming for first status

Le 17/09/2019
Merck will learn whether the FDA will approve its Ebola vaccine V920 by mid-March, giving it a shot at becoming the first company to receive clearance to sell a vaccine against the virus in the U.S....
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de Labiotech.eu
Le 29/08/2019

Never Give Up on Your Job Hunt During the Holidays!

Le 28/08/2019
Hello biotechies, Job hunt frustration? Don’t worry, we’re here to help. Check out the offer from GSK or become an Account Manager at Merck. Just starting out? Check out the internship at ADOCIA! ...
labiotech.eu
MERCK MILLIPORE
est cité dans une actualité de Labiotech.eu
Le 23/08/2019

Austrian Vaccine Developer Signs Deal with MSD in ‘Blockbuster Indication’

Le 22/08/2019
Vienna-based Themis Bioscience will develop vaccine candidates against an undisclosed disease target in partnership with big pharma Merck Sharp & Dohme. As part of the agreement, MSD will provide...
labiotech.eu
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 23/08/2019

EuroBiotech Report—Merck-Themis, Juvenescence financing, GSK filing and NuCana fail

Le 22/08/2019
In this week's EuroBiotech Report, Merck allies with Themis on vaccine R&D, Juvenescence raises $100 million and GSK files for anemia approval. ...
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 19/08/2019

Chutes & Ladders—GlaxoSmithKline poaches Merck KGaA exec to run U.S. pharma

Le 15/08/2019
GlaxoSmithKline poaches Merck KGaA's Maya Martinez-Davis to helm stateside pharma; Victor Bulto named Novartis U.S. pharma head; Allergan's Brent Saunders set for huge parachute....
www.fiercebiotech.com
MERCK MILLIPORE
est cité dans une actualité de FierceBiotech
Le 30/07/2019

Cidara posts data from head-to-head trial against Merck antifungal

Le 29/07/2019
A phase 2 trial of Cidara Therapeutics’ antifungal prospect rezafungin has met its objectives. The trial found the drug performed numerically better than Merck’s Cancidas, offering Cidara...
www.fiercebiotech.com
Charger plus d'actualités